beta

RGLS

Regulus Therapeutics Inc

Chart

Stats

Earnings

News

Splits

Dividends

Earnings

Actual EPS
Consensus EPS
Estimated EPS
Number of Estimates
EPS Surprise

Stats

Summary

regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg

Market Cap: 30.3 Million

Primary Exchange: NASDAQ

Website: http://www.regulusrx.com/

Shares Outstanding: 20.2 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 1.271673827650906

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Ethical Flags

Longest drawdown: 1938 trading days

From: 2014-11-07 To: 2024-03-07

Lowest Point:

Regulus Announces New Additions to Board of Directors

via: PR Newswire at 2019-06-11 01:00:00:000

LA JOLLA, Calif. , June 11, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Jake Nunn and Simos Simeonidis , Ph.D. have been appoint… read more...

Regulus Announces New Additions to Board of Directors

via: PR Newswire at 2019-06-11 01:00:00:000

LA JOLLA, Calif. , June 11, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Jake Nunn and Simos Simeonidis , Ph.D. have been appoint… read more...

Regulus Announces New Additions to Board of Directors

via: PR Newswire at 2019-06-11 01:00:00:000

LA JOLLA, Calif. , June 11, 2019 /PRNewswire/ -- Regulus Therapeutics Inc . (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced Jake Nunn and Simos Simeonidis , Ph.D. have been appoint… read more...

Ex-Date Payment Date Record Date Declared Date Amount Flag Dividend Type Qualified Indicated
Ex-Date Declared Date Record Date Payment Date Ratio To Factor For Factor
Data provided by IEX Cloud